Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 4, 2016
- Accepted in final form August 12, 2016
- First Published October 12, 2016.
Author Disclosures
- Catharina C. Gross, PhD*,
- Diana Ahmetspahic, MSc*,
- Tobias Ruck, MD*,
- Andreas Schulte-Mecklenbeck,
- Kathrin Schwarte,
- Silke Jörgens, PhD,
- Stefanie Scheu, PhD,
- Susanne Windhagen, MD,
- Bettina Graefe, MD,
- Nico Melzer, MD,
- Luisa Klotz, MD,
- Volker Arolt, MD,
- Heinz Wiendl, MD,
- Sven G. Meuth, MD, PhD‡ and
- Judith Alferink, MD‡
- Catharina C. Gross, PhD*,
NONE
NONE
I received speaker honoraria and travel expenses for attending meetings from Genzyme, Novartis Pharma GmbH, and Bayer Health Care.
Frontiers in Immunology, Review Editor, Since 2015
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
German Research Foundation (DFG), GR3946/2-1, 01/2013- 12/2015 German Research Foundation (DFG), SFB-CRC-TR 129,Project A09 07/2016-06/2020 BMBF grant Disease-Related Competence Network Multiple Sclerosis, Immune MS, KKNMS-030
Innovative Medical Science Grant (IMF-grant) of the medical faculty of the University of M?nster, KL111421, 07/2014-06/2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Diana Ahmetspahic, MSc*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Ruck, MD*,
NONE
NONE
TR has received travel expenses from Genzyme and Novartis and has received honoraria for lecturing from Genzyme, Biogen and Teva.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
TR has received financial research support from Genzyme and Novartis
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andreas Schulte-Mecklenbeck,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kathrin Schwarte,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Silke Jörgens, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Stefanie Scheu, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Strategic Research Fund of the Heinrich-Heine-University of D?sseldorf (SFF-F2012/79-5-Scheu)
(1) German Research Foundation (DFG SCHE692/3-1; SCHE692/4-1) (2) J?rgen Manchot Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Susanne Windhagen, MD,
NONE
NONE
Honoraria for speaking engagements from Bayer Vital, Biogen, Merck-Serono, Novartis Pharma and TEVA-Pharma.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Bettina Graefe, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Nico Melzer, MD,
NONE
NONE
1. Biogen Idec, honoraria for lecturing and travel expenses for attending meetings 2. GlaxoSmith Kline, honoraria for lecturing and travel expenses for attending meetings 3. Teva, honoraria for lecturing and travel expenses for attending meetings 4. Fresenius Medical Care, honoraria for lecturing and travel expenses for attending meetings
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Immunoadsorption, (5%), 3 years
1. Fresenius Medical Care 2. Diamed
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luisa Klotz, MD,
(1) Genzyme
NONE
(1) Novartis, speaker honoraria and travel support (2) Merck Serono, speaker honoraria and travel support (3) CSL Behring, speaker honoraria and travel support
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Biogen
(1) CRC TR128 ?Initiating/Effector versus Regulatory Mechanisms in Multiple Sclerosis ? Progress towards Tackling the Disease?, Project A8
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Volker Arolt, MD,
Advisory boards commercial: Astra-Zeneca, Eli Lilly, Janssen-Organon, Lundbeck, Otsuka, Servier, and Trommsdorff.
NONE
(1)DGPPN 2013,2014,2015; Lundbeck-Otsuka (2)Oberarzt Symposium Leipzig 2015; Servier
Der Nervenarzt; Editor since 2014 sub-editor CME since 2004
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) BMBF: PROTECT-AD,Nr 01EE1402A; PI since 2015 (2) EU FP7: Marie Curie, Nr 286334 PSYCH-AID; Partner since 2012
IZKF Medical Faculty, University of M?enster
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Heinz Wiendl, MD,
(1) Bayer Healthcare (2) Biogen Idec (3) Sanofi- Genzyme (4) Merck Serono (5) Novartis (6) Roche (7) Teva
NONE
(1) Bayer Vital GmbH (2) Bayer Schering AG (3) Biogen (4) CSL Behring (5) EMD Serono (6) Fresenius Medical Care (7) Sanofi - Genzyme (8) Merck Serono (9) Omniamed (10) Novartis (11) Teva (12) GlaxoSmithKline (13) GW Pharmaceuticals
(1) PLOS ONE, Editorial board member, since 2013 (2) Neurotherapeutics, since 2013
NONE
NONE
NONE
(1) Biogen Idec (2) Merck Serono (3) Novartis (4) Omniamed (5) Roche (6) Sanofi-Genzyme
NONE
NONE
NONE
(1) Bayer Healthcare (2) Bayer Vital (3) Biogen Idec (4) Merck Serono (5) Novartis (6) Sanofi ? Genzyme (7) Sanofi US (8) TEVA Pharma
(1) German Ministry for Education and Research (BMBF), 01GI1601E, principal investigator, 2016-2019 (2) European Union (EU), BD604219, principal investigator, 2013-2016 (3)Interdisciplinary Centre of Clinical Research (IZKF) Muenster, principal investigator, 2015-2018 (4)PML Consortium, principal investigator, 2016-2018 (5) German Research Foundation, principal investigator,SFB 1009 TP A3 + SFB-TR CRC128 TP A09 + SFB TR CRC128 TP A10, TR CRC128 TP V, TR CRC128 TP Z02 2016- 2020
NONE
(1) Else Kr?ner Fresenius Foundation (2) Fresenius Foundation (3) Hertie Foundation (4) RE Children?s Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD, PhD‡ and
(1) Almirall (2) Bayer Health Care (3) Biogen (4) Genzyme (5) Merck Serono (6) Novartis (7) Novo Nordisk (8) Roche (9) Sanofi-Aventis (10) Teva
NONE
Sven G. Meuth (SGM) has received honoraria for lecturing and travel expenses from following commercial entities with no company exceeding 10,000 ?: (1)Almirall (2)Bayer Health Care (3)Biogen (4)Genzyme (5)Merck Serono (6)Novartis (7)Roche (8)TEVA
PLoS One
NONE
NONE
NONE
(1)Biogen (2)Genzyme (3)Merck Serono (4)Novartis (5)Roche (5)TEVA
NONE
NONE
NONE
(1)Bayer Health Care (2)Biogen (3)Genzyme (4)Merck Serono (5)Novartis (6)TEVA
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Judith Alferink, MD‡
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1. Interdisciplinary Center of Clinical research (IZKF, grant Alf3/018/16), University of M?nster 2. Innovative Medizinische Forschung (IMF,grant I-DL121204), University of M?nster 3. Innovative Medizinische Forschung (IMF,grant I-ST111423), University of M?nster
DFG EXC 1003,Cells in Motion?Cluster of Excellence, M?nster, Germany (Grant FF-2014-0) Alzheimer Forschung Initiative e.V. (AFI project #148365)
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (C.C.G., T.R., A.S.-M., N.M., L.K., H.W., S.G.M.), University Hospital Münster; Department of Psychiatry (D.A., K.S., S.J., V.A., J.A.) and Cluster of Excellence EXC 1003, Cells in Motion (D.A., K.S., H.W., S.G.M.), University of Münster; Institute of Medical Microbiology and Hospital Hygiene (S.S.), University of Düsseldorf; and Department of Neurology (S.W., B.G.), Clinics Osnabrück, Germany.
- Correspondence to Dr. Alferink: Judith.Alferink{at}ukmuenster.de or Dr. Gross: Catharina.Gross{at}ukmuenster.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Editor's Corner
From brain to brawnJosep Dalmau et al.Neurology: Neuroimmunology & Neuroinflammation, December 01, 2016 -
Article
CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MSJ. Elkins, J. Sheridan, L. Amaravadi et al.Neurology - Neuroimmunology Neuroinflammation, January 28, 2015 -
Article
Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammationEkaterina Esaulova, Claudia Cantoni, Irina Shchukina et al.Neurology: Neuroimmunology & Neuroinflammation, May 05, 2020 -
Article
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumabHeinz Wiendl, Matthew Carraro, Giancarlo Comi et al.Neurology: Neuroimmunology & Neuroinflammation, October 29, 2019